

**ASX ANNOUNCEMENT**

ASX:RSH OTCQB:RSHUF

21 March 2023

**Investor presentation**

**Respiri Limited (ASX:RSH) (“Respiri” or the “Company”)**, an eHealth SaaS Company supporting respiratory health management, is pleased to announce that following a successful 2 months of operations in the USA, Marjan Mikel, Respiri CEO, invites shareholders and interested parties to an investor presentation to outline the progress made over this period.

The presentation will be made at 11am AEDT on Tuesday 28 March 2023 and the presentation deck will be released onto the ASX markets announcement platform before commencement of the presentation.

Please access the live presentation at:

<https://us02web.zoom.us/j/84927199063?pwd=U2VZUkFxYjg0d2E4SUpUMXp5S3lwQT09>

For the Q&A session, please send questions prior to the webinar to [investors@respiri.co](mailto:investors@respiri.co) by **AEDT COB 27<sup>th</sup> March 2023**

A replay of the presentation will be available at the above-mentioned Zoom link following the conclusion of the investor update.

**For further information, investors and media please contact:**

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

---

**About Respiri Limited**

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is an international e-Health SaaS company supporting respiratory health management focusing primarily on supporting the US remote patient monitoring market. Its world-first technology detects wheeze, a typical symptom of Asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri created technology optimises how patients in partnership with their physicians manage chronic respiratory conditions. These solutions can help transform the way physicians interact with respiratory patients while they are away from the clinic. wheezo®, is an FDA cleared Class II Medical Device, the respiri™ app (patient-user-interface) and the secure health portal can help different health organisations and providers connect with patients to improve collaboration and help improve respiratory condition management. In the USA, wheezo® can be integrated into Remote Patient Monitoring (RPM) programs and qualifies for RPM Current Procedural Terminology (CPT) reimbursement.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world with respiratory disorders and dramatically reduce hospital admissions and the economic burden of Asthma and COPD. Respiri Limited's operations are based in Melbourne, Australia with offices in New York City, USA.

For additional information about Respiri Limited please visit our corporate website [www.respiri.co/au](http://www.respiri.co/au)

---

**About wheezo®**

Developed in Australia, with the support of an international panel leading respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the intuitive mobile application engages patients to log symptoms and triggers to build a personal profile to share data with healthcare providers so patients and physicians can have more informed discussions in relation to symptoms. The platform has been designed to extend care beyond the clinic which may lead to better health outcomes and improved quality of life for patients.

For information about our product offering in the US including wheezo® please visit [www.respiri.co/us](http://www.respiri.co/us)

wheezo® is a registered trademark of Respiri Limited.

**About Access Telehealth**

Access Telehealth is a digital health company dedicated to delivering innovative connected care solutions for management of people living with chronic disease. The Remotli platform uniquely simplifies remote care delivery with patient engagement and productivity driven dashboard tools to support effective patient care and compliance. Automated care-time tracking, and reimbursement reports makes it easy to boost revenue to support vital chronic disease management programs including Remote Physiologic Monitoring, Remote Therapeutic Monitoring, Transitional Care, Chronic Care Management, Telemedicine and more. Focusing on Remote Physiologic Monitoring and virtual care initiatives, the Access Telehealth clinical team delivers patient-centric

**ASX ANNOUNCEMENT**

ASX:RSH OTCQB:RSHUF

remote monitoring services to support disease specific chronic care programs for health systems, payors, and providers, to enhance care delivery. [www.accessrpm.com/](http://www.accessrpm.com/)